Last reviewed · How we verify
NCT05495087
IHT for Mild Cognitive Impairment
NA trial testing IHT Treatment in Mild Cognitive Impairment in 66 participants. Status unknown.
30 April 2025
Quick facts
| Lead sponsor | University of North Texas Health Science Center |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 27 February 2023 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- IHT Treatment
- Sham-IHT Control
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Memory Impairment — all drugs for Memory Impairment →
Sponsor
University of North Texas Health Science Center
Who can join
Adults 55 to 80, any sex, with Mild Cognitive Impairment or Memory Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I clinical trial will examine the safety and efficacy of intermittent hypoxia training (IHT) for up to 12 weeks to treat subjects with mild cognitive impairment (MCI).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches.
Loeffler DA. · · 2024 · cited 2× · PMID 38872626 · DOI 10.3389/fnagi.2024.1368200
Verify or expand the search:
- PubMed search for NCT05495087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other University of North Texas Health Science Center trials
Trials by the same sponsor.
- NCT06025630 — Targeting Endoplasmic Reticulum Stress in Human Hypertension · Phase 1, PHASE2 · recruiting
- NCT04978129 — Enhancing Quality in Protective Strategies · NA · completed
- NCT04333966 — Parental Research on Interventions for Social Media · NA · completed
- NCT05706181 — Heat Therapy, Functional Capacity, and Vascular Health in Older Adults · Phase 1, PHASE2 · recruiting
- NCT03750838 — Alcohol Intervention for First Year College Students · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05495087 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of North Texas Health Science Center
- Last refreshed: 6 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing